Anzeige
Erschienen in:
01.06.2017 | original article
Fecal occult blood test/fecal carcinoembriogenic antigen dual rapid test as a useful tool for colorectal cancer screening
Erschienen in: European Surgery | Ausgabe 3/2017
Einloggen, um Zugang zu erhaltenSummary
Background
There are several screening tools for colorectal cancer (CRC). Most are limited in their application. The fecal occult blood test (FOBT) is a first-step screen for CRC that is limited by low sensitivity. This study aimed to prove the efficacy of combined FOBT and fecal carcinoembryogenic antigen (fCEA) as a CRC screening test.
Methods
Stool samples were collected preoperatively from 166 CRC patients expected to undergo elective surgery and from normal control patients. A fecal CEA/FOBT dual kit was created and the results from the use of this dual kit were compared against other clinicopathologic parameters.
Results
FOBT was positive in 103 of the 166 (62.0%) CRC patients and fCEA was positive in 114 (68.7%) patients, showing a statistically positive relationship. Among 63 FOBT negative patients, 29 (17%) cases were CEA positive. Thus, the CEA/FOBT dual test could detect CRC in 79.5% of the patients (132/166). The sensitivity and specificity of the dual FOBT/CEA test was 79.5% and 97.9%, respectively.
Conclusions
The FOBT/CEA dual test has increased sensitivity compared to the FOBT test and may have merit as a screening device for colorectal cancer. Population-based studies are required to confirm this potential.
